BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Cervical cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for cervical cancer: 521 (317 sponsors; 62 newly posted in the last 180 days, 24 stopped in the last 180 days; 31 new-entrant sponsors). Momentum score 9.6, rank 73 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 7, Phase 1 159, Phase 2 207, Phase 3 66, Phase 4 8, N/A 74.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
CSPC Megalith Biopharmaceutical Co.,Ltd.7P3 5, P2 230
Sichuan Baili Pharmaceutical Co., Ltd.27P2 15, P1 8, P3 4510
AstraZeneca AZN16P2 7, P3 4, NA 1, P1 403
Akeso5P3 4, P2 102
Merck Sharp & Dohme LLC MRK11P2 6, P4 1, P3 3, NA 111
Exelixis EXEL6P3 2, P1 3, P4 102
Genmab GMAB5P3 2, P2 300
Lepu Biopharma Co., Ltd.4P2 2, P3 200
Rakuten Medical, Inc.3P3 2, P2 100
MediLink Therapeutics (Suzhou) Co., Ltd.4P2 3, P3 101
Suzhou Suncadia Biopharmaceuticals Co., Ltd.4P3 1, P2 301
Bicara Therapeutics BCAX3P2 1, P3 1, P1 110
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3P2 1, NA 1, P3 102
Daiichi Sankyo3P3 1, P2 200
GlaxoSmithKline3P3 1, P1 1, P2 100
Hansoh BioMedical R&D Company3P2 2, P3 110
Jazz Pharmaceuticals JAZZ3P3 1, NA 1, P2 111
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY3P2 2, P3 120
Aveta Biomics, Inc.2P2 1, P3 111
Beijing Konruns Pharmaceutical Co., Ltd.2P3 1, P2 101
Inhibrx Biosciences, Inc INBX2P2 1, P3 100
Janssen Research & Development, LLC2P2 1, P3 100
Jiangsu Alphamab Biopharmaceuticals Co., Ltd2P2 1, P3 110
Jiangsu HengRui Medicine Co., Ltd.2P3 1, P2 100
Johnson & Johnson Enterprise Innovation Inc. JNJ2P3 1, P1 100

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05990803 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological MalignanciesCervical Cancerrecruiting130
2026-12 est.P1/P2Theravectys S.A.NCT06319963 A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal CancerHPV-Related Cervical Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinomarecruiting72
2026-12-27 est.P2Amplexd Therapeutics, Inc.NCT07572396 Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic AbnormalitiesHigh-risk HPV (Any Strain); LSIL, Low Grade Squamous Intraepithelial Lesion; ASC-US; HPV Infection; recruiting45
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P2Shanghai Henlius BiotechNCT06769152 A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant TumorsCervical Cancer; Ovarian Cancerrecruiting190
2026-12-31 est.P1/P2Evopoint Biosciences Inc.NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsAdvanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancersrecruiting350
2027-01-31 est.P2Grit BiotechnologyNCT06241781 Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancerrecruiting100
2027-01-31 est.P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07202364 A Study of YL202 in Patients With Advanced Solid TumorsNon Small Cell Lung Cancer; Colorectal Cancer; Cervical Cancer; Locally Advanced or Metastatic Solidrecruiting100

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-11 est.P2Precigen, Inc PGENNCT06157151 PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerCervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Recurrent Cervical Carcinoma; Metastrecruiting24
2026-10 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancerrecruiting100
2026-09 est.P2/P3Bio-Thera SolutionsNCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerCervical Cancerrecruiting526
2026-08 est.P2Tasly Biopharmaceuticals Co., Ltd.NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsRecurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervicnot yet recruiting120
2026-06-17P1/P2Precision Biologics, Inc DTILNCT03476681 Study of NEO-201 in Solid Tumors Expansion CohortsNon Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Canceractive not recruiting121

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "cervical cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.